icIEF Sample Matrix for PEGylated Protein Charge Separation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Imaged capillary isoelectric focusing (icIEF) methods struggle to effectively separate and resolve charge variants of PEGylated proteins, resulting in broad and distorted peaks due to the masking effect of polyethylene glycol chains, which complicates isoelectric focusing and reduces the ability to accurately determine the isoelectric point and quantify charge species.
Innovation Solution
A novel icIEF sample matrix comprising glycine and/or taurine, with specific concentration ranges, is introduced to enhance the separation of PEGylated proteins, reducing matrix-induced baseline interference and enabling the discrimination of charge variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional icIEF methods are used for PEGylated proteins, then the isoelectric focusing process can be performed, but the peak shapes become broad and distorted due to masking by polyethylene glycol chains
Solution Approach 1:
The patent introduces an intermediary substance (specific surfactant or additive) into the icIEF sample matrix to mediate the interaction between PEGylated proteins and the separation medium. This intermediary reduces the masking effect of polyethylene glycol chains, allowing charge variants to be properly resolved without altering the fundamental icIEF process.
Solution Approach 2:
The patent modifies parameters of the sample matrix, specifically adjusting pH, ionic strength, and adding specific additives to optimize the separation conditions for PEGylated proteins. These parameter changes counteract the broadening effect of PEG chains and improve peak shape resolution.
2Reliability
If PEG chains are conjugated to proteins to enhance pharmacokinetic properties, then immunogenicity and toxicity are reduced, but charge variant discrimination becomes difficult due to masking effects
Solution Approach 1:
The patent employs an intermediary agent in the sample matrix that specifically addresses the masking effect caused by PEG chains. This intermediary enables the detection and quantification of charge variants without compromising the therapeutic benefits of PEGylation, allowing simultaneous maintenance of both protein stability and analytical precision.
Solution Approach 2:
The patent changes matrix parameters such as pH and ionic composition to optimize the electrooptical properties during separation, thereby improving the ability to distinguish charge variants of PEGylated proteins while preserving their therapeutic characteristics.
3Manufacturing precision
If various additives are added to the sample matrix to improve separation, then some peak shape improvement may be achieved, but reasonable peak shapes and charge variant discrimination remain unattainable
Solution Approach 1:
The patent identifies a specific intermediary substance that effectively resolves both peak shape and charge variant separation issues simultaneously. This targeted approach replaces the trial-and-error addition of various additives with a proven effective intermediary that addresses both problems in one solution.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The icIEF sample matrix with glycine and taurine improves peak resolution and separation of PEGylated proteins, allowing for accurate determination of the isoelectric point and quantification of discrete species, enhancing assay repeatability and robustness.
Implementation Method 1
Imaged capillary isoelectric focusing (icIEF) is the current industry standard for determining the isoelectric point (pI) of proteins as well as relative quantification of charge species
Implementation Method 2
Isoelectric focusing sample matrix... imaged capillary isoelectric focusing analysis of PEGylated proteins
Data Source
AI summary
The present disclosure provides icIEF sample matrices that enable icIEF analysis of PEGylated proteins in their real conjugated states. The sample matrices of the present disclosure can include glycine, which enables the separation of co-migrated PEGylated protein charge variants. The sample matrices can also include taurine, which further improves icIEF assay by depleting matrix induced baseline interferences. Accordingly, a sample matrix of the present disclosure including a combination of glycine and taurine enables icIEF separation of acidic and basic species from the main peak for PEGylated proteins, allowing the identification/separation, characterization and quantification of discrete PEGylated protein species. By using the sample matrices of the present disclosure to characterize PEGylated proteins by icIEF, repeatability, linearity, accuracy, sample stability, and method robustness are achieved.